SCHEMBL20848110

SCHEMBL20848110

CCOC(=O)[C@H]1CCCN(C(=O)C(C)Oc2ccc3c(-c4ccccc4C)cc(=O)oc3c2)C1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 1/20 0.56
▸ CYP2C9 P11712 1/20 0.56
▸ CYP2C19 P33261 1/20 0.56
▸ ALDH1A1 P00352 9/20 0.53
▸ KDM4E B2RXH2 5/20 0.53
▸ MAPT P10636 2/20 0.51
▸ RAB9A P51151 3/20 0.51
▸ HPGD P15428 5/20 0.49
▸ KMT2A Q03164 7/20 0.49
▸ MEN1 O00255 6/20 0.49
▸ TSHR P16473 2/20 0.46
▸ USP2 O75604 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.46
▸ SMN1; SMN2 Q16637 2/20 0.46
▸ NPC1 O15118 1/20 0.46
▸ HTT P42858 2/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ GAA P10253 1/20 0.45
▸ LMNA P02545 1/20 0.44
▸ RECQL P46063 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30056612 1.00 CYP3A4 (0.56) CYP3A4CYP2C9CYP2C19ALDH1A1KDM4E
SCHEMBL30055214 0.93 MAPT (0.57) CYP3A4CYP2C9CYP2C19ALDH1A1KDM4E
SCHEMBL20848109 0.93 MAPT (0.57) CYP3A4CYP2C9CYP2C19ALDH1A1KDM4E
SCHEMBL30055797 0.92 CYP3A4 (0.57) CYP3A4CYP2C9CYP2C19ALDH1A1KDM4E
SCHEMBL20839469 0.92 CYP3A4 (0.57) CYP3A4CYP2C9CYP2C19ALDH1A1KDM4E
SCHEMBL21629626 0.91 RAB9A (0.62) CYP3A4CYP2C9CYP2C19ALDH1A1KDM4E
SCHEMBL21648250 0.91 RAB9A (0.62) CYP3A4CYP2C9CYP2C19ALDH1A1KDM4E
SCHEMBL21629625 0.91 RAB9A (0.62) CYP3A4CYP2C9CYP2C19ALDH1A1KDM4E
SCHEMBL31089640 0.91 RAB9A (0.62) CYP3A4CYP2C9CYP2C19ALDH1A1KDM4E
SCHEMBL20839095 0.90 CYP3A4 (0.59) CYP3A4CYP2C9CYP2C19ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111386261-B Coumarin derivatives, process for their preparation and their use in the treatment of cancer 利德发现中心有限责任公司 2024-03-22 — — CN claimed
EP-3684762-B1 COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER LEAD DISCOVERY CENTER GMBH (DE) 2023-05-03 — — EP claimed
CN-111386261-B Coumarin derivatives, process for their preparation and their use in the treatment of cancer 利德发现中心有限责任公司 2024-03-22 — — CN disclosed
US-11111238-B2 Coumarin derivatives, processes for their preparation and uses thereof for the treatment of cancer LEAD DISCOVERY CENTER GMBH (DE) 2021-09-07 — — US disclosed
US-20200291011-A1 COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER LEAD DISCOVERY CENTER GMBH (DE) 2020-09-17 — — US disclosed
WO-2019057821-A1 COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER LEAD DISCOVERY CENTER GMBH (DE) 2019-03-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11111238-B2 Coumarin derivatives, processes for their preparation and uses thereof for the treatment of cancer POLRMT, UQCRC2, UQCRC1 CYP3A4 248/4885CYP2C9 473/4885CYP2C19 543/4885
US-20200291011-A1 COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER POLRMT, UQCRC2, UQCRC1 CYP3A4 248/4885CYP2C9 473/4885CYP2C19 543/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback